Technical Analysis for ENTO - Entero Therapeutics Inc.

Grade Last Price % Change Price Change
F 0.42 3.69% 0.01
ENTO closed down 1.74 percent on Wednesday, November 20, 2024, on 19 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 3.69%
Narrow Range Bar Range Contraction 3.69%
Lower Bollinger Band Walk Weakness 3.69%
Wide Bands Range Expansion 3.69%
Below Lower BB Weakness 3.69%
Down 3 Days in a Row Weakness 3.69%
Down 4 Days in a Row Weakness 3.69%
Down 5 Days in a Row Weakness 3.69%
Lower Bollinger Band Touch Weakness 3.69%
Oversold Stochastic Weakness 3.69%

   Recent Intraday Alerts

Alert Time
Down 1% 34 minutes ago
60 Minute Opening Range Breakdown 43 minutes ago
Rose Above Lower Bollinger Band about 4 hours ago
Up 3% about 4 hours ago
Up 2% about 4 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmacy Medication Gastrointestinal Disease Gastrointestinal Tract Covid 19

Is ENTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.5
52 Week Low 0.1873
Average Volume 450,527
200-Day Moving Average 2.19
50-Day Moving Average 0.50
20-Day Moving Average 0.60
10-Day Moving Average 0.55
Average True Range 0.08
RSI (14) 34.64
ADX 30.76
+DI 16.61
-DI 25.70
Chandelier Exit (Long, 3 ATRs) 0.50
Chandelier Exit (Short, 3 ATRs) 0.63
Upper Bollinger Bands 0.79
Lower Bollinger Band 0.41
Percent B (%b) -0.03
BandWidth 62.70
MACD Line -0.03
MACD Signal Line 0.01
MACD Histogram -0.0376
Fundamentals Value
Market Cap 625.8 Thousand
Num Shares 1.56 Million
EPS 1131.40
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 2.56
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.46
Resistance 3 (R3) 0.46 0.44 0.45
Resistance 2 (R2) 0.44 0.43 0.44 0.45
Resistance 1 (R1) 0.42 0.42 0.41 0.42 0.44
Pivot Point 0.40 0.40 0.40 0.40 0.40
Support 1 (S1) 0.38 0.39 0.37 0.38 0.36
Support 2 (S2) 0.36 0.38 0.36 0.35
Support 3 (S3) 0.34 0.36 0.35
Support 4 (S4) 0.34